Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)

M De Santis, P J Wiechno, J Bellmunt, C Lucas, W-C Su, L Albiges, C-C Lin, E Senkus-Konefka, A Flechon, L Mourey, A Necchi, W C Loidl, M M Retz, N Vaissière, S Culine, M De Santis, P J Wiechno, J Bellmunt, C Lucas, W-C Su, L Albiges, C-C Lin, E Senkus-Konefka, A Flechon, L Mourey, A Necchi, W C Loidl, M M Retz, N Vaissière, S Culine

Abstract

Background: There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting.

Patients and methods: Patients with aUC a creatinine clearance (CrCl) of <60 but ≥30 ml/min, performance status 0 or 1 and no prior chemotherapy for advanced disease were randomized (1 : 1). They received vinflunine 250 or 280 mg/m(2) (based on baseline CrCl) on day 1, plus either gemcitabine [750 mg/m(2) escalated to 1000 mg/m(2) in cycle 2 if no toxicity grade (G) ≥2 on days 1 and 8 (VG) or plus carboplatin area under the curve 4.5 day 1 (VC) every 21 days]. To detect a 22% improvement in each arm compared with H0 (41%) in the primary end point, disease control rate (DCR = complete response + partial response + stable disease), 31 assessable patients per arm were required (α = 5%, β = 20%).

Results: Sixty-nine patients were enrolled (34 VG, 35 VC). Less G3/4 haematological adverse events (AEs) were reported with VG: neutropaenia was seen in 38% (versus 68% with VC) and febrile neutropaenia in 3% (versus 14% with VC) of patients. No major differences were observed for non-haematological AEs. DCR was 77% in both groups; overall response rate (ORR) was 44.1% versus 28.6%, with a median progression-free survival of 5.9 versus 6.1 months and median OS of 14.0 versus 12.8 months with VG and VC, respectively.

Conclusion: Both vinflunine-based doublets offer a similar DCR, ORR and OS. The better haematological tolerance favours the VG combination, which warrants further study. CLINICALTRIALS.GOV PROTOCOL IDENTIFIER: NCT 01599013.

Trial registration: ClinicalTrials.gov NCT01599013.

Keywords: bladder cancer; cisplatin-ineligible; renal impairment; urothelial carcinoma; vinflunine.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

References

    1. International Agency for Research on Cancer, World Health Organisation. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. (18 August 2014, date last accessed).
    1. Bellmunt J, Orsola A, Leow JJ et al. . Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(suppl 3): iii40–iii48.
    1. Witjes JA, Compérat E, Cowan NC et al. . EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014; 65(4): 778–792.
    1. Galsky MD, Hahn NM, Rosenberg J et al. . A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12(3): 211–214.
    1. De Santis M, Bellmunt J, Mead G et al. . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191–199.
    1. Galsky MD, Hahn NM, Rosenberg J et al. . Treatment of patients with metastatic urothelial cancer ‘unfit’ for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29(17): 2432–2438.
    1. Javlor® European Public Assessment Report doc EMEA/CHMP/370293/2009.
    1. Bellmunt J, Théodore C, Demkov T et al. . Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454–4461.
    1. Isambert N, Delord JP, Tourani JM et al. . How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol 2014; 77(3): 498–508.
    1. Tournoux-Facon C, Senellart H, Lemarie E et al. . Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in chemonaive patients. J Thorac Oncol 2011; 6(7): 1247–1253.
    1. Tournoux-Facon C, Robinet G, Pinel MC et al. . Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer. Am J Clin Oncol 2012; 35(4): 378–385.
    1. Bamias A, Moulopoulos LA, Koutras A et al. . The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006; 106: 297–303.
    1. De Santis M, Bellmunt J, Mead G et al. . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 2009; 27(33): 5634–5639.
    1. Culine S, Fléchon A, Guillot A et al. . Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). Eur Urol 2011; 60(6): 1251–1257.
    1. Galsky MD, Iasonos A, Mironov S et al. . Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109(3): 549–555.
    1. Bajorin DF, Dodd PM, Mazumdar M et al. . Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173–3181.
    1. Balar AV, Apolo AB, Ostrovnaya I et al. . Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013; 31(6): 724–730.
    1. Venook A, Egorin M, Rosner G et al. . Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer Leukemia Group B 9565. J Clin Oncol 2000; 18(14): 2780–2787.
    1. Serrate C, Pouessel D, Gauthier H et al. . Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies. Clin Invest 2014; 4(4): 305–311.
    1. Meluch AA, Greco FA, Burris HA III et al. . Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19(12): 3018–3024.
    1. Albers P, Park SI, Niegisch G et al. . Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22(2): 288–294.
    1. Pond GR, Bellmunt J, Fougeray R et al. . Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer 2013; 11(4): 495–500.
    1. Sonpavde G, Bellmunt J, Rosenberg JE et al. . Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer 2014; 12(6): 395–398.
    1. Krajewski KM, Fougeray R, Bellmunt J et al. . Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer 2012; 48(10): 1495–1502.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj